Consumers are in for a relief as prices of drugs in the National List of Essential Medicines (NLEM) will remain flat, in line with the change in the wholesale price index (WPI) this year.
In a notification issued on Wednesday, the National Pharmaceutical Pricing Authority (NPPA) said the annual change in WPI worked out to be 0.005 per cent during the calendar year 2023 over 2022. According to Para 16(2) of the Drug Price Control Order (DPCO) 2013, the manufacturers may increase the maximum retail price (MRP) of scheduled drugs on the basis of this WPI, the notification said.
Therefore, effectively, in 2024 the prices of NLEM drugs or scheduled drugs will remain flat. The price hikes allowed (in line with change in WPI) were 12.12 per cent in 2023 and 10.7 per cent in 2022, respectively.
This story is from the March 29, 2024 edition of Business Standard.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the March 29, 2024 edition of Business Standard.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber? Sign In
Chennai In Wait-And-Watch Mode: Will CSK Paint The Town Yellow?
Come Saturday, hundreds and thousands of Chennai's 6.6 million people, and millions of fans outside the city, will be rooting for Chennai Super Kings (CSK) as they clash against Royal Challengers Bangalore (RCB).
Financial Markets Prefer Stability, Predictability: FM
Warns of unchecked explosion in F&O retail trades
I Never Do Hindu-Muslim Politics: Modi
Celebrated Eid; Oppn tarnished image among Muslims after 2002: PM
India's Al Spend May Touch $5 bn By 2027
Spending on artificial intelligence (AI) in India is expected to grow at a compound annual growth rate of 31.5 per cent from 2023 and might reach $5.1 billion by 2027, according to a joint study released on Tuesday by Intel and International Data Corporation (IDC).
Multiple launches to boost Cipla's margin prescription
The shares of pharma major Cipla slipped by about 4 per cent on Tuesday, after gaining over 5.6 per cent a day earlier.
Novelis files papers in US for IPO
Novelis, Hindalco Industries' US subsidiary, has filed a registration statement on Form F1 for its proposed initial public offering (IPO) with US securities regulator Securities and Exchange Commission (SEC), the firm said.
MF investment strategy: Be wary of rich valuations
Mutual fund investors are in the crosshairs due to the widespread offloading of stocks by foreign institutional investors (FIIs), expensive valuations of the Indian markets compared to global peers, and nervousness ahead of the Lok Sabha election results.
MFS EMBRACE HEALTHCARE, FINANCE STOCKS AS SMALLCAPS BOUNCE BACK
Mutual funds (MFS) embraced smallcap shares across sectors like healthcare, hospitality, and financial services, as the net inflows bounced back in April from the March lows.
JSPL stock factoring in improving prospects
THE COMPASS DEVANGSHU DATTA Jindal Steel & Power's (JSPL's) Q4FY24 results were in line with consensus.
Ease penal action for glitches, Mils appeal to Sebi
Regulator to seek suggestions applicability of financial disincentives